Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof

A compound represented by formula (I), a racemate, a stereoisomer, a tautomer, an isotope-labeled counterpart, a solvate, a polymorph, a pharmaceutically acceptable salt thereof or a prodrug thereof:

• wherein ring A is selected from a C3-14 carbocyclic ring, a C6-14 aromatic ring, a 5- to 14-membered heteroaromatic ring, or a 3- to 14-membered heterocyclic ring, wherein the C3-14 carbocyclic ring, C6-14 aromatic ring, 5- to 14-membered heteroaromatic ring and 3- to 14-membered heterocyclic ring are each independently unsubstituted or optionally substituted with one, two or more Ra;
• each Ra is the same or different and is independently selected from H, deuterium, OH, halogen, cyano, NH2, or the following groups which are unsubstituted or optionally substituted with one, two or more Ra1:
• C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, Ra11—C(═O)—NH—, Ra12—C(═O)—, Ra13—S(═O)2—NH—, Ra14—S(═O)2—, —P(═O)(Ra15)(Ra16), (Ra17)(Ra18)N—C(═O)—, C6-14 aryl, 5- to 14-membered heteroaryl, 3- to 14-membered heterocyclyl, or C3-14 cycloalkyl;
• each Rai is the same or different and is independently selected from H, deuterium, OH, halogen, CN, C1-12 alkyl, C3-12 cycloalkyl, C1-12 alkoxy, or halo-C1-12 alkyl;
• Ra11, Ra12, Ra13, Ra14, Ra15, Ra16, Ra17, and Ra18 are the same or different and are each independently selected from H, deuterium, halogen, CN, C1-12 alkyl, or C1-12 alkoxy;
• ring B is selected from a C6-14 aromatic ring, a 5- to 14-membered heteroaromatic ring, a 3- to 14-membered heterocyclic ring, or a C3-14 carbocyclic ring, wherein the C6-14 aromatic ring, 5- to 14-membered heteroaromatic ring, 3- to 14-membered heterocyclic ring and C3-14 carbocyclic ring are each independently unsubstituted or optionally substituted with one, two or more Rb;
• each Rb is the same or different and is independently selected from H, deuterium, OH, halogen, cyano, NH2, or the following groups which are unsubstituted or optionally substituted with one, two or more Rb1:
• C1-12 alkyl, or C1-12 alkoxy;
• each Rb1 is the same or different and is independently selected from H, deuterium, halogen, CN, C1-12 alkyl, or C1-12 alkoxy;
• R1 is selected from H, deuterium, halogen, CN, hydroxyl, amino, C1-6 alkyl, halo-C1-6 alkyl, cyano-C1-6 alkyl, or C3-8 cycloalkyl;
• Q is selected from a chemical bond or C1-6 alkylene;
• R2 is selected from the following groups which are unsubstituted or optionally substituted with one, two or more R2a:
• C1-12 alkyl, C1-12 alkoxy, C6-14 aryl, 5- to 14-membered heteroaryl, 3- to 14-membered heterocyclyl, or C3-14 cycloalkyl;
• each R2a is the same or different and is independently selected from H, deuterium, halogen, CN, OH, carboxyl, or the following groups which are unsubstituted or optionally substituted with one, two or more R2a1:
• C1-12 alkyl, C1-12 alkoxy, or R21—C(═O)—(CH2)m—;
• or two R2a together with the carbon atom to which they are attached form C3-8 cycloalkyl or 3-8 membered heterocyclyl;
• each R2a1 is the same or different and is independently selected from H, deuterium, halogen, CN, carboxyl, C1-12 alkyl, C1-12 alkoxy, or R22—C(═O)—;
• each R21 and R22 are the same or different and are each independently selected from H, deuterium, halogen, CN, OH, amino, C1-12 alkylamino, (C1-12 alkyl)2amino, C3-12 cycloalkylamino, C1-12 alkyl, C1-12 alkoxy, C3-8 cycloalkyl, or 3- to 14-membered heterocyclyl;
• m is an integer selected from 0 to 6;
• alternatively, R2 is selected from
• which is unsubstituted or optionally substituted with one, two or more Re, wherein ring E is selected from C3-8 cycloalkyl;
• R11 and R12 are the same or different and are each independently selected from H, halogen, C1-6 alkyl, halo-C1-6 alkyl, cyano-C1-6 alkyl, C3-8 cycloalkyl, halo-C3-8 cycloalkyl or cyano-C3-8 cycloalkyl;
• each Re is the same or different and is independently selected from H, OH, halogen, cyano, NH2, or the following groups which are unsubstituted or optionally substituted with one, two or more Re1:
• C1-6 alkyl, or C3-8 cycloalkyl;
• each Re1 is the same or different and is independently selected from H, OH, halogen, or cyano;
• alternatively, R2 is selected from
• which is unsubstituted or optionally substituted with one, two or more Rf, wherein ring F is selected from 4- to 8-membered heterocyclic ring;
• R13 is selected from H, or the following groups which are unsubstituted or optionally substituted with one, two or more R13a:
• C1-6 alkyl, C3-8 cycloalkyl, or R13b—C(═O)—(CH2)s—;
• R13b is selected from C1-6 alkyl, C3-8 cycloalkyl or amino;
• each R13a is the same or different and is independently selected from H, OH, halogen, cyano, or C1-6 alkyl;
• s is selected from integers of 0 to 6;
• each Rf is the same or different and is independently selected from H, OH, halogen, cyano, NH2, or the following groups which are unsubstituted or optionally substituted with one, two or more Rf1:
• C1-6 alkyl, or C3-8 cycloalkyl;
• each Rf1 is the same or different and is independently selected from H, OH, halogen, or cyano.